Annual report pursuant to Section 13 and 15(d)

Segment Reporting

v3.7.0.1
Segment Reporting
12 Months Ended
Jun. 30, 2017
Segment Reporting [Abstract]  
Segment Reporting Disclosure [Text Block]
17.
Segment Reporting
 
In accordance with FASB ASC 280, “Segment Reporting,” the Company discloses financial and descriptive information about its reportable segments. The Company operates in two segments, iBio, Inc. and iBio CDMO. Commencing July 1, 2016, management determined that the activity of iBio CDMO should be segregated as a separate segment. In addition, management determined that the activity of iBio Brazil was no longer material and will be included in the activity of iBio, Inc. As such, the segment information for the year ended June 30, 2016 was conformed to the current presentation. These segments are components of the Company about which separate financial information is available and regularly evaluated by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The accounting policies of the segments are the same as those described in the Summary of Significant Accounting Policies.
 
Year Ended June 30, 2017 (in thousands)
 
iBio, Inc.
 
iBio CDMO
 
Eliminations
 
Total
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenues - external customers
 
$
271
 
$
123
 
$
-
 
$
394
 
Revenues - intersegment
 
 
972
 
 
1,280
 
 
(2,252)
 
 
-
 
Research and development
 
 
3,657
 
 
1,763
 
 
(1,303)
 
 
4,117
 
General and administrative
 
 
5,245
 
 
6,255
 
 
(949)
 
 
10,551
 
Operating loss
 
 
(7,659)
 
 
(6,615)
 
 
-
 
 
(14,274)
 
Interest expense
 
 
(1)
 
 
(1,928)
 
 
-
 
 
(1,929)
 
Interest and other income
 
 
43
 
 
21
 
 
-
 
 
64
 
Consolidated net loss
 
 
(7,617)
 
 
(8,522)
 
 
-
 
 
(16,139)
 
Total assets
 
 
19,049
 
 
29,738
 
 
(12,777)
 
 
36,010
 
Fixed assets, net
 
 
8
 
 
25,581
 
 
-
 
 
25,589
 
Intangible assets, net
 
 
1,823
 
 
-
 
 
-
 
 
1,823
 
Depreciation expense
 
 
3
 
 
1,323
 
 
-
 
 
1,326
 
Amortization of intangible assets
 
 
350
 
 
-
 
 
-
 
 
350
 
 
Year Ended June 30, 2016 (in thousands)
 
iBio, Inc.
 
iBio CDMO *
 
Eliminations
 
Total
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenues - external customers
 
$
893
 
$
55
 
$
-
 
$
948
 
Revenues - intersegment
 
 
158
 
 
324
 
 
(482)
 
 
-
 
Research and development
 
 
2,984
 
 
501
 
 
(329)
 
 
3,156
 
General and administrative
 
 
5,560
 
 
2,278
 
 
(153)
 
 
7,685
 
Operating loss
 
 
(7,493)
 
 
(2,400)
 
 
-
 
 
(9,893)
 
Interest expense
 
 
-
 
 
(807)
 
 
-
 
 
(807)
 
Interest and other income
 
 
33
 
 
10
 
 
-
 
 
43
 
Consolidated net loss
 
 
(7,460)
 
 
(3,197)
 
 
-
 
 
(10,657)
 
Total assets
 
 
13,393
 
 
38,282
 
 
(75)
 
 
51,600
 
Fixed assets, net
 
 
8
 
 
25,566
 
 
-
 
 
25,574
 
Intangible assets, net
 
 
2,092
 
 
-
 
 
-
 
 
2,092
 
Depreciation expense
 
 
4
 
 
573
 
 
-
 
 
577
 
Amortization of intangible assets
 
 
363
 
 
-
 
 
-
 
 
363
 
 
*
iBio CDMO commenced operations in December 2015.